Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 16/20 | 0.77 |
| ▸ | NPC1 | O15118 | 1/20 | 0.76 |
| ▸ | RAB9A | P51151 | 1/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.63 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.62 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.61 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8175404 | 0.87 | RAB9A (0.89) | NAMPTNPC1RAB9ASMN1; SMN2HIF1A | |
| SCHEMBL5427744 | 0.87 | NPC1 (1.00) | NPC1RAB9ASMN1; SMN2HIF1AHDAC1 | |
| SCHEMBL20379284 | 0.87 | NAMPT (1.00) | NAMPT | |
| SCHEMBL17916794 | 0.85 | SMN1; SMN2 (0.88) | NAMPTNPC1RAB9ASMN1; SMN2HIF1A | |
| SCHEMBL17831080 | 0.85 | NPC1 (0.84) | NAMPTNPC1RAB9ASMN1; SMN2HIF1A | |
| SCHEMBL163178 | 0.83 | NAMPT (1.00) | NAMPTCYP2C9 | |
| SCHEMBL26101164 | 0.82 | NPC1 (0.80) | NAMPTNPC1RAB9ASMN1; SMN2HIF1A | |
| SCHEMBL23747417 | 0.82 | NPC1 (0.71) | NAMPTNPC1RAB9ASMN1; SMN2HIF1A | |
| SCHEMBL23747763 | 0.81 | NPC1 (0.78) | NPC1RAB9ASMN1; SMN2HIF1AHDAC1 | |
| SCHEMBL26097972 | 0.81 | NPC1 (0.80) | NPC1RAB9ASMN1; SMN2HIF1AHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230133132-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230133132-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230133132-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-05-04 | — | — | US | disclosed |
| WO-2021159015-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133132-A1 | NAMPT MODULATORS | NAMPT, MC4R, SIRT1 | NAMPT 1/4885NPC1 463/4885RAB9A 807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.